查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081927

癌症治療和支持治療藥物市場：2026-2032年全球市場預測（按藥物類型、給藥途徑、作用機制、適應症、分銷管道和最終用戶分類）

Cancer Therapeutics & Supportive Care Drugs Market by Drug Type, Route Of Administration, Mechanism of Action, Indication, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，癌症治療和支持護理市場將成長至 4,115.8 億美元，複合年成長率為 10.66%。

主要市場統計數據
基準年 2025 2024.3億美元
預計年份：2026年 2234.7億美元
預測年份 2032 4115.8億美元
複合年成長率 (%) 10.66%

癌症治療和支持性護理市場正從以劑量主導的癌症治療市場轉向以生物標記檢測、標靶治療治療、免疫腫瘤學、放射性配體療法、抗體藥物複合體（ADC）、生物相似藥和症狀管理方案為基礎的精準實證生態系統。臨床需求依然顯著且可衡量。根據國際癌症研究機構（IARC）發布的《2022年全球癌症風險評估報告》（GLOBOCAN 2022），全球預計將新增約2,000萬例癌症病例，並有970萬人死於癌症。隨著人口老化和持續存在的風險因素，預計到2050年，新增病例將超過3500萬例。

對於創新生物製藥公司的領導者而言，經營團隊的首要任務是在提高生存率的同時，保障病患的生活品質。支持性治療產品，包括止吐藥、髓系生長因子、骨調節劑、止痛藥、感染預防劑、治療相關毒性的藥物，不再是次要產品。它們是提高劑量強度、確保治療連續性以及實現以患者為中心的癌症治療的關鍵要素。

癌症治療藥物領域的變革性變化

癌症治療格局正因早期診斷、分子水平分層以及基於特定腫瘤生物學設計的療法的快速發展而重塑。免疫查核點抑制劑、PARP抑制劑、BTK抑制劑、CDK4/6抑制劑、雙特異性抗體、CAR-T細胞療法、抗體藥物偶聯物（ADC）以及新一代內分泌和激酶抑制劑已經徹底改變了骨髓惡性腫瘤和固體癌的治療路徑。

人工智慧在癌症治療中的累積影響

人工智慧（AI）的應用並非局限於單一領域，其影響正累積滲透到癌症治療的整個價值鏈。在藥物發現階段，AI驅動的蛋白質建模、標靶辨識和分子最佳化能夠縮短假設檢驗週期。在藥物開發階段，機器學習可輔助進行患者篩選、合成對照組搜尋、臨床試驗中心選擇、方案可行性評估、影像學審查以及藥物監測訊號檢測。

主要區域洞察：亞太地區、北美地區、歐洲、拉丁美洲、中東和非洲

亞太地區，包括中國、日本、韓國、印度和澳洲等市場，由於大規模的患者群體、不斷提升的篩檢能力、不斷完善的醫院基礎設施以及標靶治療的快速普及，成為癌症治療的重點區域。中國持續擴大在癌症治療領域的國內創新和生技藥品生產能力，而日本和韓國在精準醫療、免疫腫瘤學和高品質生產體系方面仍然發揮著至關重要的作用。印度正在加強其三級癌症治療、學名藥、生物相似藥和公共衛生舉措，而澳洲則維持其基於實證醫學的保險報銷體系，並繼續積極參與臨床研究。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

在東協市場，透過對公立醫院的投資、全民健保計畫以及私人醫療機構的發展，癌症治療的可近性正在不斷擴大。然而，由於報銷機制的差異，分級定價、本地夥伴關係、醫生培訓以及診斷服務的可近性至關重要。海灣合作理事會（GCC）優先發展專科癌症中心、篩檢計畫、醫療旅遊策略和先進療法，從而為符合國際指南的高品質癌症藥物和支持性治療方案創造機會。

重點癌症治療市場關鍵國家洞察

美國是許多癌症治療藥物的核心市場，這得益於其高密度的臨床試驗、生物標記的快速應用、FDA在癌症審查方面的專業能力、先進的癌症中心以及在臨床和准入決策中廣泛使用真實世界數據（REW）。在加拿大，醫療技術評估、省級報銷方案、全國性審查流程和公平准入至關重要，因此，證明臨床價值和可行性的證據對於推廣應用至關重要。

為癌症治療行業的領導者提供的實用建議

產業領導者應在癌症治療方案的早期研發階段就融入支持性治療。臨床試驗方案應包含與劑量調整、不利事件管理、患者報告症狀、住院、感染疾病、疼痛、噁心、疲勞和生活品質（QOL）相關的終點指標（如臨床適用）。

調查方法

本執行摘要是基於對公開權威來源的三角分析，包括國際癌症研究機構 (IARC) 的 GLOBOCAN 癌症負擔估計、世界衛生組織 (WHO) 關於癌症和基本藥物的指南、美國食品藥品監督管理局 (FDA) 和歐洲藥品管理局 (EMA) 的監管材料、美國國家綜合癌症網路 (NCCN) 和美國臨床腫瘤學會 (ASCOTA)的支持性護理資訊來源參考資料以及同儕審查的腫瘤學文獻。

結論

癌症治療和支持性護理正朝著更一體化的腫瘤學模式發展，在這種模式下，療效、耐受性、可近性和真實世界的臨床結果決定了其長期價值。創新將持續進行，但成功的機構必須證明，新療法既能提高患者的生存率和日常生活功能，又能符合支付方、醫療保健系統和患者承受經濟負擔的能力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 癌症治療與支持治療藥物市場：依藥物類型分類

  • 癌症治療藥物
    • 化療
    • 標靶治療
    • 免疫療法
    • 荷爾蒙療法
    • 細胞和基因治療
    • 單株抗體
  • 支持治療藥物
    • 止吐藥
    • 止痛藥
    • 生長因子
    • 雙磷酸鹽類藥物
    • 皮質類固醇

第8章：癌症治療與支持治療藥物市場：依給藥途徑分類

  • 肌肉內部
  • 靜脈
  • 口服
  • 皮下

第9章：癌症治療與支持治療藥物市場：依作用機制分類

  • 細胞毒性
  • 免疫系統調節
  • 標靶分子抑制
  • 抑制荷爾蒙通路
  • 抑制骨吸收

第10章 癌症治療與支持治療藥物市場：依適應症分類

  • 乳癌
  • 結腸癌
  • 白血病
  • 肺癌
  • 淋巴瘤

第11章 癌症治療與支持治療藥物市場：按分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專科藥房

第12章 癌症治療與支持治療藥物市場：依最終使用者分類

  • 醫院
  • 腫瘤診所
  • 專科癌症中心

第13章 癌症治療與支持治療藥物市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 癌症治療與支持治療藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 癌症治療與支持性治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Blueprint Medicines Corporation
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Clovis Oncology, Inc.
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • HUTCHMED Limited
  • Incyte Corporation
  • Ipsen SA
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • MacroGenics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Seagen Inc.
  • Takeda Pharmaceutical Company Limited
  • TG Therapeutics, Inc.
Product Code: MRR-4316E4E89554

The Cancer Therapeutics & Supportive Care Drugs Market is projected to grow by USD 411.58 billion at a CAGR of 10.66% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 202.43 billion
Estimated Year [2026] USD 223.47 billion
Forecast Year [2032] USD 411.58 billion
CAGR (%) 10.66%

Cancer therapeutics and supportive care drugs are moving from a volume-driven oncology market to a precision, evidence-based ecosystem anchored in biomarker testing, targeted medicines, immuno-oncology, radioligand therapy, antibody-drug conjugates, biosimilars, and symptom-management protocols. The clinical need remains large and measurable: IARC's GLOBOCAN 2022 estimated about 20 million new cancer cases and 9.7 million cancer deaths worldwide, with new cases projected to rise to more than 35 million by 2050 as populations age and risk factors persist.

For innovative biopharma leaders, the executive priority is to improve survival while protecting quality of life. Supportive care drugs, including antiemetics, myeloid growth factors, bone-modifying agents, pain medicines, infection prophylaxis, and therapies for treatment-related toxicities, are no longer secondary products; they are essential enablers of dose intensity, treatment persistence, and patient-centered cancer care.

Transformative Shifts in the Oncology Drug Landscape

The oncology landscape is being reshaped by earlier diagnosis, molecular stratification, and the rapid expansion of therapies designed around specific tumor biology. Immune checkpoint inhibitors, PARP inhibitors, BTK inhibitors, CDK4/6 inhibitors, bispecific antibodies, CAR-T cell therapies, ADCs, and next-generation endocrine and kinase inhibitors have changed treatment pathways across hematologic malignancies and solid tumors.

At the same time, affordability and access are becoming decisive competitive factors. Biosimilars for supportive care and oncology biologics have expanded treatment options in many markets, while value-based reimbursement is pushing manufacturers to prove real-world benefit, safety, and patient-reported outcomes. The strongest portfolios will pair differentiated clinical efficacy with toxicity management, companion diagnostics, guideline alignment, and scalable access strategies.

Cumulative Impact of Artificial Intelligence in Oncology

Artificial intelligence is becoming cumulative across the cancer medicine value chain rather than confined to a single use case. In discovery, AI-enabled protein modeling, target identification, and molecule optimization can shorten hypothesis cycles. In development, machine learning is supporting patient selection, synthetic control exploration, site selection, protocol feasibility, imaging review, and pharmacovigilance signal detection.

The most valuable AI applications for cancer therapeutics and supportive care drugs will be those that meet regulatory-grade evidence standards. FDA, EMA, and other agencies increasingly expect transparent data provenance, model validation, bias assessment, and lifecycle monitoring. For biopharma companies, AI should be treated as a governed operating capability that improves trial productivity, label expansion planning, safety surveillance, and personalized supportive care algorithms.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East and Africa

Asia-Pacific is a high-priority oncology region because it combines large patient populations, rising screening capacity, expanding hospital infrastructure, and faster adoption of targeted therapies in markets such as China, Japan, South Korea, India, and Australia. China continues to increase domestic oncology innovation and biologics capacity, while Japan and South Korea remain important for precision medicine, immuno-oncology, and high-quality manufacturing systems. India is strengthening tertiary cancer care, generics, biosimilars, and public health initiatives, while Australia maintains evidence-based reimbursement and strong clinical research participation.

North America remains the leading region for oncology drug innovation, supported by the U.S. FDA approval pathway, federally funded cancer research, National Cancer Institute programs, comprehensive cancer centers, biomarker testing infrastructure, and sophisticated payer systems. Canada adds a strong health technology assessment environment and provincial reimbursement processes that emphasize clinical benefit, budget discipline, and equitable access to cancer therapeutics and supportive care medicines.

Europe offers broad clinical research depth through Germany, France, Italy, Spain, the United Kingdom, and Nordic markets, although health technology assessment, reference pricing, and price negotiation strongly shape uptake. The European regulatory environment increasingly emphasizes comparative evidence, pharmacovigilance, real-world data, and cross-border collaboration, making early evidence planning critical for oncology drug launches and supportive care adoption.

Latin America, the Middle East, and Africa show substantial unmet need in access to diagnostics, essential cancer medicines, and palliative care. Brazil and Mexico anchor Latin American demand, with public procurement and private care shaping availability. GCC countries in the Middle East are investing in oncology centers, screening, precision medicine capabilities, and specialized care. Across Africa, the strategic opportunity is to expand essential medicines, safe chemotherapy delivery, pathology capacity, opioid access for cancer pain, oncology workforce training, and reliable supportive care supply.

Key Group Insights Across ASEAN, GCC, European Union, BRICS, G7 and NATO

ASEAN markets are expanding oncology access through public hospital investment, universal coverage initiatives, and growing private-sector care, but reimbursement variability makes tiered pricing, local partnerships, physician education, and diagnostic access important. The GCC is prioritizing specialized cancer centers, screening programs, medical tourism strategies, and advanced therapeutics, creating opportunities for premium oncology drugs and supportive care protocols aligned with international guidelines.

The European Union remains central to regulatory harmonization, pharmacovigilance, health technology assessment reform, and cross-border oncology research, while joint clinical assessment will increasingly influence launch sequencing and evidence requirements. BRICS countries combine large disease burden with strong policy interest in domestic manufacturing, biosimilars, generics, technology transfer, and local clinical trials, creating demand for durable access models and locally relevant evidence.

G7 markets provide deep opportunities for novel oncology products but demand strong comparative efficacy, safety monitoring, real-world outcomes, cost-effectiveness, and supply reliability. NATO membership is not an oncology market structure, but many NATO countries overlap with high-income health systems where medicine security, resilient supply chains, emergency preparedness, and clinical readiness are policy priorities that can influence oncology drug procurement and supportive care availability.

Key Country Insights for Priority Oncology Markets

The United States is the central launch market for many cancer therapeutics due to clinical trial density, rapid biomarker adoption, FDA oncology review expertise, advanced cancer centers, and broad use of real-world evidence in clinical and access decisions. Canada emphasizes health technology assessment, provincial reimbursement, pan-Canadian review processes, and equitable access, making evidence of clinical value and implementation feasibility essential.

Mexico and Brazil represent major Latin American oncology opportunities, with demand shaped by public procurement, private insurance growth, specialized oncology services, pathology capacity, and access to biosimilars and essential supportive care medicines. Brazil's large public health system and private hospital networks create distinct access pathways, while Mexico's fragmented reimbursement environment increases the importance of affordability and local stakeholder engagement.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are priority oncology markets, each balancing innovation access with payer scrutiny and health-system sustainability. Germany's early benefit assessment, France's reimbursement system, and the United Kingdom's NICE evaluations are particularly influential for value demonstration. Italy and Spain place strong emphasis on regional implementation and budget controls. Russia remains a sizeable oncology market but is affected by geopolitical, regulatory, localization, and supply-chain complexity.

China is scaling oncology innovation, clinical trial activity, domestic biologics, and national reimbursement pathways, while India is expanding generics, biosimilars, oncology hospitals, and tertiary cancer care amid persistent affordability challenges. Japan maintains high standards for precision oncology, evidence-based reimbursement, and aging-population cancer management. Australia supports evidence-based reimbursement through national assessment processes and the Pharmaceutical Benefits Scheme, while South Korea combines strong biopharma manufacturing, digital health capacity, and fast adoption of advanced oncology technologies.

Actionable Recommendations for Oncology Industry Leaders

Industry leaders should design cancer therapeutics with supportive care integrated from the earliest development stages. Trial protocols should capture dose modification, adverse-event management, patient-reported symptoms, hospitalization, infection, pain, nausea, fatigue, and quality-of-life endpoints where clinically appropriate.

Commercial strategy should align evidence generation with payer needs by combining randomized trial data, real-world evidence, biomarker testing pathways, and health economic models. Companies should also strengthen manufacturing resilience for sterile injectables, biologics, cold-chain products, radiopharmaceuticals, and essential supportive medicines to reduce shortage risk.

Organizations should prioritize companion diagnostics, guideline integration, patient navigation, adherence support, and equitable access programs to improve outcomes beyond approval. Building region-specific reimbursement dossiers, local clinical evidence, and supply continuity plans will improve readiness for oncology launches across mature and emerging health systems.

Research Methodology

The executive summary is based on triangulation of publicly available, authoritative sources, including IARC GLOBOCAN cancer burden estimates, WHO cancer and essential medicines guidance, FDA and EMA regulatory materials, NCCN and ASCO supportive care guidance, national reimbursement frameworks, health technology assessment references, and peer-reviewed oncology literature.

The research approach prioritizes verified epidemiology, regulatory evidence, treatment guideline relevance, market-access dynamics, pharmacovigilance expectations, supply-chain considerations, and regional health-system context. Insights were synthesized to support strategic decision-making for cancer therapeutics and supportive care drugs without relying on unverified proprietary claims, market sizing, market share, or forecasting.

Conclusion

Cancer therapeutics and supportive care drugs are converging into a more integrated oncology model where efficacy, tolerability, access, and real-world outcomes determine long-term value. Innovation will remain strong, but successful organizations must prove that new treatments improve survival and daily functioning while fitting payer, health-system, and patient affordability constraints.

The most competitive organizations will combine precision medicine, disciplined AI adoption, global evidence generation, resilient supply chains, and equitable access planning. In an environment defined by rising cancer incidence, complex treatment pathways, and constrained budgets, clinically meaningful differentiation and dependable supportive care will be the strongest drivers of sustainable oncology leadership.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cancer Therapeutics & Supportive Care Drugs Market, by Drug Type

  • 7.1. Cancer Therapeutics
    • 7.1.1. Chemotherapy
    • 7.1.2. Targeted Therapy
    • 7.1.3. Immunotherapy
    • 7.1.4. Hormonal Therapy
    • 7.1.5. Cell & Gene Therapy
    • 7.1.6. Monoclonal Antibodies
  • 7.2. Supportive Care Drugs
    • 7.2.1. Antiemetics
    • 7.2.2. Analgesics
    • 7.2.3. Growth Factors
    • 7.2.4. Bisphosphonates
    • 7.2.5. Corticosteroids

8. Cancer Therapeutics & Supportive Care Drugs Market, by Route Of Administration

  • 8.1. Intramuscular
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Subcutaneous

9. Cancer Therapeutics & Supportive Care Drugs Market, by Mechanism of Action

  • 9.1. Cytotoxic Activity
  • 9.2. Immune System Modulation
  • 9.3. Targeted Molecular Inhibition
  • 9.4. Hormonal Pathway Suppression
  • 9.5. Bone Resorption Inhibition

10. Cancer Therapeutics & Supportive Care Drugs Market, by Indication

  • 10.1. Breast Cancer
  • 10.2. Colorectal Cancer
  • 10.3. Leukemia
  • 10.4. Lung Cancer
  • 10.5. Lymphoma

11. Cancer Therapeutics & Supportive Care Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies
  • 11.4. Specialty Pharmacies

12. Cancer Therapeutics & Supportive Care Drugs Market, by End User

  • 12.1. Hospitals
  • 12.2. Oncology clinics
  • 12.3. Specialty cancer centers

13. Cancer Therapeutics & Supportive Care Drugs Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Cancer Therapeutics & Supportive Care Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cancer Therapeutics & Supportive Care Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Amgen Inc.
  • 17.3. Astellas Pharma Inc.
  • 17.4. AstraZeneca PLC
  • 17.5. Bayer AG
  • 17.6. BeiGene, Ltd.
  • 17.7. Blueprint Medicines Corporation
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Bristol-Myers Squibb Company
  • 17.10. Clovis Oncology, Inc.
  • 17.11. Daiichi Sankyo Company, Limited
  • 17.12. Eli Lilly and Company
  • 17.13. Exelixis, Inc.
  • 17.14. F. Hoffmann-La Roche Ltd
  • 17.15. Gilead Sciences, Inc.
  • 17.16. HUTCHMED Limited
  • 17.17. Incyte Corporation
  • 17.18. Ipsen S.A.
  • 17.19. Jazz Pharmaceuticals plc
  • 17.20. Johnson & Johnson Services, Inc.
  • 17.21. Karyopharm Therapeutics Inc.
  • 17.22. MacroGenics, Inc.
  • 17.23. Merck & Co., Inc.
  • 17.24. Novartis AG
  • 17.25. Pfizer Inc.
  • 17.26. Regeneron Pharmaceuticals, Inc.
  • 17.27. Sanofi S.A.
  • 17.28. Seagen Inc.
  • 17.29. Takeda Pharmaceutical Company Limited
  • 17.30. TG Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HORMONAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HORMONAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HORMONAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIEMETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIEMETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIEMETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANALGESICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANALGESICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GROWTH FACTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GROWTH FACTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GROWTH FACTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BISPHOSPHONATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BISPHOSPHONATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BISPHOSPHONATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CYTOTOXIC ACTIVITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CYTOTOXIC ACTIVITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CYTOTOXIC ACTIVITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNE SYSTEM MODULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNE SYSTEM MODULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNE SYSTEM MODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TARGETED MOLECULAR INHIBITION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TARGETED MOLECULAR INHIBITION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TARGETED MOLECULAR INHIBITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HORMONAL PATHWAY SUPPRESSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HORMONAL PATHWAY SUPPRESSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HORMONAL PATHWAY SUPPRESSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BONE RESORPTION INHIBITION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BONE RESORPTION INHIBITION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BONE RESORPTION INHIBITION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ONCOLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ONCOLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ONCOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL SPECIALTY CANCER CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SPECIALTY CANCER CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SPECIALTY CANCER CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. GCC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. GCC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. GCC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 178. GCC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 179. GCC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. GCC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 181. GCC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 182. GCC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. GCC CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. G7 CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. G7 CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 205. G7 CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 206. G7 CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. G7 CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 208. G7 CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 209. G7 CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. G7 CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. NATO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. NATO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 214. NATO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 215. NATO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. NATO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 217. NATO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. NATO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. NATO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. CANADA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. CANADA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. CANADA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 233. CANADA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 234. CANADA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. CANADA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 236. CANADA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. CANADA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. CANADA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. MEXICO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. MEXICO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. MEXICO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 242. MEXICO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 243. MEXICO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. MEXICO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 245. MEXICO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 246. MEXICO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. MEXICO CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. BRAZIL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. BRAZIL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. BRAZIL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 251. BRAZIL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 252. BRAZIL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. BRAZIL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 254. BRAZIL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 255. BRAZIL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. BRAZIL CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED KINGDOM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED KINGDOM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED KINGDOM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED KINGDOM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED KINGDOM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED KINGDOM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED KINGDOM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED KINGDOM CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. GERMANY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 269. GERMANY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 270. GERMANY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 271. GERMANY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 272. GERMANY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 273. GERMANY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. GERMANY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. FRANCE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. FRANCE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. FRANCE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 278. FRANCE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 279. FRANCE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. FRANCE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 281. FRANCE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 282. FRANCE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 283. FRANCE CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. RUSSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 287. RUSSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 288. RUSSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. RUSSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 290. RUSSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 291. RUSSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. RUSSIA CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. ITALY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. ITALY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. ITALY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 296. ITALY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 297. ITALY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 298. ITALY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 299. ITALY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 300. ITALY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 301. ITALY CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. SPAIN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. SPAIN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 305. SPAIN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 306. SPAIN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 307. SPAIN CANCER THERAPEUTICS & SUPPORTIVE CARE DRUGS MARKET SIZE, BY MECHANI